title: Clinical Implications of Hepatocyte Growth Factor, Interleukin-20, and Interleukin-22 in Serum and Bronchoalveolar Fluid of Patients with Non-Small Cell Lung Cancer.
abstract: Hepatocyte growth factor (HGF) is involved in tumorigenesis, interleukin-20 (IL-20) is an inhibitor of angiogenesis, and interleukin-22 (IL-22) stimulates tumor growth. The aim of this study was to determine the level of HGF, IL-20, and IL-22 in both serum and bronchoalveolar lavage fluid (BALF) of non-small cell lung cancer (NSCLC) patients before onset of chemotherapy, the nature of the interrelationships between these markers, and their prognostic significance regarding post-chemotherapy survival time. We studied 46 NSCLC patients and 15 healthy subjects as a control group. We found significantly higher serum levels of HGF and IL-22 in the NSCLC patients than those in controls [pg/ml: HGF - 1911 (693-6510) vs. 1333 (838-3667), p = 0.0004; IL-22 - 10.66 (1.44-70.34) vs. 4.69 (0.35-12.29), p = 0.0007]. In contrast, concentrations of HGF and IL-22 in BALF were lower in NSCLC patients than those in controls [pg/ml: HGF - 72 (6-561) vs. 488 (14-2003), p = 0.0002; IL-22 - 2.28 (0.70-6.52) vs. 3.72 (2.76-5.64), p = 0.002]. In the NSCLC patients, there was a negative correlation between the serum level of IL-20 and time to tumor progression (r = -0.405, p = 0.04) and between the serum level of HGF and survival time (r = -0.41, p = 0.005). In addition, a higher serum level of HGF and a higher BALF level of IL-22 in patients were linked with a shorter overall survival. We conclude that HGF, IL-20, and IL-22 in the serum and BALF of NSCLC patients before chemotherapy may be a prognostic of cancer progression.
authors: Department of Lung Diseases, Medical University of Bialystok, 14 Zurawia Street, 15-540, Bialystok, Poland. wojciechnaumnik@gmail.com.|Department of Clinical Molecular Biology, Medical University of Bialystok, Bialystok, Poland. wojciechnaumnik@gmail.com.
authors: W
authors: W
authors: Naumnik
authors: First Department of Nephrology and Transplantation with Dialysis Unit, Medical University of Bialystok, Bialystok, Poland.
authors: B
authors: B
authors: Naumnik
authors: Department of Histology and Embryology, Medical University of Bialystok, Bialystok, Poland.
authors: W
authors: W
authors: Niklińska
authors: Department of Lung Diseases, Medical University of Bialystok, 14 Zurawia Street, 15-540, Bialystok, Poland.
authors: M
authors: M
authors: Ossolińska
authors: Department of Lung Diseases, Medical University of Bialystok, 14 Zurawia Street, 15-540, Bialystok, Poland.
authors: E
authors: E
authors: Chyczewska
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis / Q000097:blood; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry*; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood / Q000175:diagnosis* / Q000188:drug therapy; D002945:Cisplatin / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D018450:Disease Progression; D004797:Enzyme-Linked Immunosorbent Assay; D017228:Hepatocyte Growth Factor / Q000032:analysis* / Q000097:blood; D006801:Humans; D007378:Interleukins / Q000032:analysis* / Q000097:blood; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016896:Treatment Outcome; D000093542:Gemcitabine; D000097043:Interleukin-22
chemical_list: D014408:Biomarkers, Tumor; D002945:Cisplatin; D003841:Deoxycytidine; D017228:Hepatocyte Growth Factor; D007378:Interleukins; D000093542:Gemcitabine; D000097043:Interleukin-22; C422042:interleukin 20
keywords: Bronchoalveolar lavage fluid; Hepatocyte growth factor; Interelukin-22; Interleukin-20; Non-Small Cell Lung Cancer